Pneumocystis Jirovecii Pneumonia After Rituximab Therapy for Antibody-mediated Rejection in a Renal Transplant Recipient

Overview

Journal Transpl Infect Dis

Specialties General Surgery
Infectious Diseases

Date 2008 Sep 23

PMID 18803617

Citations 9

Authors

D Kumar

S Gourishankar

T Mueller

S Cockfield

J Weinkauf

D Vethanayagam

A Humar

Affiliations

Soon will be listed here.

Abstract

We report the case of a 54-year-old woman who underwent living-related renal transplantation for end-stage renal disease from IgA nephropathy. She was subsequently diagnosed with antibody-mediated rejection (AMR) and received rituximab, a potent B-cell suppressive agent. After therapy with rituximab, she developed Pneumocystis jirovecii pneumonia (PJP) requiring hospitalization. We discuss the increasing literature for the use of rituximab for AMR and the need for PJP prophylaxis in this setting.

Citing Articles

Hypogammaglobulinemia, late-onset neutropenia, and infections following rituximab.

Athni T, Barmettler S Ann Allergy Asthma Immunol. 2023; 130(6):699-712.

PMID: 36706910 PMC: 10247428. DOI: 10.1016/j.anai.2023.01.018.

Metagenomic Next-Generation Sequencing in Diagnosis of a Case of Pneumonia in a Kidney Transplant Recipient and Literature Review.

Chen J, He T, Li X, Wang X, Peng L, Ma L Infect Drug Resist. 2020; 13:2829-2836.

PMID: 32884306 PMC: 7431457. DOI: 10.2147/IDR.S257587.

Management of Pneumocystis jirovecii Pneumonia in Kidney Transplantation to Prevent Further Outbreak.

Goto N, Futamura K, Okada M, Yamamoto T, Tsujita M, Hiramitsu T Clin Med Insights Circ Respir Pulm Med. 2015; 9(Suppl 1):81-90.

PMID: 26609250 PMC: 4648609. DOI: 10.4137/CCRPM.S23317.

Pneumocystis jiroveci prophylaxis in patients undergoing Bendamustine treatment: the need for a standardized protocol.

Abkur T, Saeed M, Ahmed S, McArthur R, Leahy M, OLeary H Clin Case Rep. 2015; 3(4):255-9.

PMID: 25914820 PMC: 4405313. DOI: 10.1002/ccr3.195.

Prophylaxis and Treatment of Pneumocystis jiroveci Pneumonia in Lymphoma Patients Subjected to Rituximab-Contained Therapy: A Systemic Review and Meta-Analysis.

Jiang X, Mei X, Feng D, Wang X PLoS One. 2015; 10(4):e0122171.

PMID: 25909634 PMC: 4409297. DOI: 10.1371/journal.pone.0122171.